LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

Meadow Creek Wealth Advisors LLC decreased its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 7.7% during the ...

Eli Lilly and Company, Pfizer, Merck & Co., Inc., AbbVie, and Thermo Fisher Scientific are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical ...

As obesity management draws awareness and weight-loss injections are launched in India, hospitals are offering customised ...

The Delhi High Court has instructed India's drug regulator to address concerns about the approval process for drugs like ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical ...

The healthcare sector, represented by the Health Care Select Sector SPDR Fund (NYSEARCA:XLV), underperformed the broader ...